Dizal Pharmaceutical Co. Ltd.

Clinical research in advanced non-small cell lung cancer focuses on tumours carrying EGFR or HER2 mutations, including EGFR exon 20 insertion variants and locally advanced or metastatic disease. The sponsor’s activity in this area reflects a strong interest in molecularly defined lung cancer populations and targeted treatment options.

• EGFR-mutated lung cancer
• HER2-mutated lung cancer
• EGFR exon 20 insertion
• Metastatic disease

Research sites across multiple countries support treatment development for patients whose disease is defined by specific oncogenic drivers in the respiratory oncology setting.